Interluekin-35 in Asthma and Its Potential as an Effective Therapeutic Agent
Interleukin- (IL-) 35 is a member of the IL-12 cytokine family and a heterodimeric protein formed by Epstein-Barr-induced gene 3 (EBI3) and IL-12p35. Emerging evidence shows that IL-35 is a key player in the regulation of cellular communication, differentiation, and inflammation. Altered IL-35 expre...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2017/5931865 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849472082547572736 |
|---|---|
| author | Peng Gao Zhenzhong Su Xuejiao Lv Jie Zhang |
| author_facet | Peng Gao Zhenzhong Su Xuejiao Lv Jie Zhang |
| author_sort | Peng Gao |
| collection | DOAJ |
| description | Interleukin- (IL-) 35 is a member of the IL-12 cytokine family and a heterodimeric protein formed by Epstein-Barr-induced gene 3 (EBI3) and IL-12p35. Emerging evidence shows that IL-35 is a key player in the regulation of cellular communication, differentiation, and inflammation. Altered IL-35 expression has been found in disease conditions such as cancer, rheumatoid arthritis, and, more recently, asthma. In cancer, IL-35 is involved in the regulation of tumorigenesis, cancer progression, and metastasis. In rheumatoid arthritis, IL-35 acts as a negative regulator of inflammation. Similarly, IL-35 also appears to suppress allergic inflammation in asthma. In an in vivo murine model of asthma, transfer of adenovirus-mediated IL-35 markedly reduced the degree of airway hyperresponsiveness (AHR) and inflammatory cell infiltration. Many studies have shown the involvement of IL-35 in a number of aspects of allergic inflammation, such as eosinophil and neutrophil recruitment as well as inhibition of inflammatory mediators of the Th2 subtype. However, the exact molecular mechanisms underlying the role of IL-35 in human asthma have yet to be fully elucidated. This review describes the current evidence regarding the role of IL-35 in the pathophysiology of asthma and evaluates the potential of IL-35 as a biomarker for airway inflammation and a therapeutic target for the treatment of asthma. |
| format | Article |
| id | doaj-art-e99bc3955ec843bd9068d1186f7501b6 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-e99bc3955ec843bd9068d1186f7501b62025-08-20T03:24:37ZengWileyMediators of Inflammation0962-93511466-18612017-01-01201710.1155/2017/59318655931865Interluekin-35 in Asthma and Its Potential as an Effective Therapeutic AgentPeng Gao0Zhenzhong Su1Xuejiao Lv2Jie Zhang3Department of Respiratory Medicine, The Second Affiliated Hospital of Jilin University, Changchun, ChinaDepartment of Respiratory Medicine, The Second Affiliated Hospital of Jilin University, Changchun, ChinaDepartment of Respiratory Medicine, The Second Affiliated Hospital of Jilin University, Changchun, ChinaDepartment of Respiratory Medicine, The Second Affiliated Hospital of Jilin University, Changchun, ChinaInterleukin- (IL-) 35 is a member of the IL-12 cytokine family and a heterodimeric protein formed by Epstein-Barr-induced gene 3 (EBI3) and IL-12p35. Emerging evidence shows that IL-35 is a key player in the regulation of cellular communication, differentiation, and inflammation. Altered IL-35 expression has been found in disease conditions such as cancer, rheumatoid arthritis, and, more recently, asthma. In cancer, IL-35 is involved in the regulation of tumorigenesis, cancer progression, and metastasis. In rheumatoid arthritis, IL-35 acts as a negative regulator of inflammation. Similarly, IL-35 also appears to suppress allergic inflammation in asthma. In an in vivo murine model of asthma, transfer of adenovirus-mediated IL-35 markedly reduced the degree of airway hyperresponsiveness (AHR) and inflammatory cell infiltration. Many studies have shown the involvement of IL-35 in a number of aspects of allergic inflammation, such as eosinophil and neutrophil recruitment as well as inhibition of inflammatory mediators of the Th2 subtype. However, the exact molecular mechanisms underlying the role of IL-35 in human asthma have yet to be fully elucidated. This review describes the current evidence regarding the role of IL-35 in the pathophysiology of asthma and evaluates the potential of IL-35 as a biomarker for airway inflammation and a therapeutic target for the treatment of asthma.http://dx.doi.org/10.1155/2017/5931865 |
| spellingShingle | Peng Gao Zhenzhong Su Xuejiao Lv Jie Zhang Interluekin-35 in Asthma and Its Potential as an Effective Therapeutic Agent Mediators of Inflammation |
| title | Interluekin-35 in Asthma and Its Potential as an Effective Therapeutic Agent |
| title_full | Interluekin-35 in Asthma and Its Potential as an Effective Therapeutic Agent |
| title_fullStr | Interluekin-35 in Asthma and Its Potential as an Effective Therapeutic Agent |
| title_full_unstemmed | Interluekin-35 in Asthma and Its Potential as an Effective Therapeutic Agent |
| title_short | Interluekin-35 in Asthma and Its Potential as an Effective Therapeutic Agent |
| title_sort | interluekin 35 in asthma and its potential as an effective therapeutic agent |
| url | http://dx.doi.org/10.1155/2017/5931865 |
| work_keys_str_mv | AT penggao interluekin35inasthmaanditspotentialasaneffectivetherapeuticagent AT zhenzhongsu interluekin35inasthmaanditspotentialasaneffectivetherapeuticagent AT xuejiaolv interluekin35inasthmaanditspotentialasaneffectivetherapeuticagent AT jiezhang interluekin35inasthmaanditspotentialasaneffectivetherapeuticagent |